Chromosomal fragility syndrome and family history of radiosensitivity as indicators for radiotherapy dose modification.
Beside a few known radiosensitive syndromes, a patient's reaction to radiotherapy is difficult to predict. In this report we describe the management of a pediatric cancer patient presented with a family history of radiosensitivity and cancer proneness. Laboratory investigations revealed a chromosomal fragility syndrome and an increased cellular radiosensitivity in vitro. AT gene sequencing revealed no mutations. The patient was treated with reduced radiation doses to avoid the presumed increased risks of toxicity to normal tissues. The patient tolerated well the treatment with no significant acute or late radiation sequelae. Five years later, the patient remains both disease and complications free. While an accurate laboratory test for radiosensitivity is still lacking, assessments of chromosomal fragility, cell survival and clinical medicine will continue to be useful for a small number of patients.
Alsbeih
Ghazi
G
Experimental Radiation Oncology, Box 66, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Story
Michael D
MD
Maor
Moshe H
MH
Geara
Fady B
FB
Brock
William A
WA
D002528:Cerebellar Neoplasms / Q000235:genetics / Q000532:radiotherapy*; D002675:Child, Preschool; D002873:Chromosome Fragility; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007621:Karyotyping; D008527:Medulloblastoma / Q000235:genetics / Q000532:radiotherapy*; D011829:Radiation Dosage